Chronic Pain Is a Hidden Epidemic. It’s Time for a Revolution.
I would have been bored, except the pain was so tiring that I could barely function. I spent the days shuffling around the ...
Buy Rating for Mediwound Driven by EscharEx’s Market Potential and Disruptive Role in Chronic Wound Care
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Mediwound (MDWD – Research Report). The associated price target ...
HealthPrep on MSN2d
Top ten unmistakable warning signs of stomach ulcers you can't afford to ignore
Stomach ulcers, clinically known as peptic ulcers, are a prevalent health issue that often goes unnoticed until it becomes ...
PharmiWeb6d
Negative Pressure Wound Therapy Industry to Reach USD 10.8 Billion by 2033, Growing at a 5.3% CAGR
Negative Pressure Wound Therapy IndustryThe global negative pressure wound therapy (NPWT) market is projected to grow from an estimated valuation of USD 6.5 billion in 2023 to USD 10.8 billion by 2033 ...
PharmiWeb6d
Global Chronic Wound Care Market Set to Grow at a Robust CAGR of 3.8% by 2033: FMI
The global chronic wound care market is poised for significant growth, with a projected rise at a Compound Annual Growth Rate (CAGR) of 3.8% from 2023 to 2033. The market value is forecasted to ...
Verywell Health on MSN7d
Dermatitis Types and Treatment Options
Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...
Compression Therapy Market Technologies and Applications Analysis 2025, with Profiles of Major Companies Operating in this Space
Global Compression Therapy Market Projected to Reach $5.6 Billion by 2030, Driven by Innovations and Aging Population ...
Future Market Insights11d
Global Venous Stents Industry Poised for Rapid Growth, Expected to Reach USD 2.2 Billion by 2033
Venous Stents Industry. According to the latest industry analysis from Future Market Insights, the global venous stents ...
Pharmaceutical Technology12d
Amesanar by RHEACELL for Diabetic Foot Ulcers: Likelihood of Approval
Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...
Pharmaceutical Technology13d
Sulodexide by Alfasigma for Venous Thromboembolism: Likelihood of Approval
Sulodexide is under clinical development by Alfasigma and currently in Phase III for Venous Thromboembolism. According to GlobalData, Phase III drugs for Venous Thromboembolism have a 60% phase ...
Couriermail23d
‘Spreading’: Victoria Health issues grim warning as flesh-eating Buruli Ulcer disease moves across the state
A gruesome flesh-eating bacteria – suspected to be transmitted by an iconic animal – is spreading in one Aussie state, and health officials are warning everyone is at risk. Victoria’s Health ...